Diabetes, obesity & metabolism · 2025
Immunogenicity, efficacy and safety of a biosimilar insulin glulisine compared with originator in adults with type 1 diabetes mellitus: A phase III randomised clinical trial.
СтатьяКлиническое исследование III фазыРандомизированное исследованиеМногоцентровое исследованиеСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Drai Roman, Galstyan Gagik, Karonova Tatiana, Protsenko Ekaterina, Parfenova Tatyana, Arefeva Anna, Matvienko Iuliia, Iliushchenko Dmitrii, Makarenko Igor
Аннотация
AIMS: To evaluate the immunogenicity, efficacy, and safety of a biosimilar insulin glulisine candidate (T-Glu) compared to the reference product (R-Glu) in patients with type 1 diabetes mellitus (T1DM).
MATERIALS AND METHODS: In this phase III, randomised, open-label trial, adult patients with T1DM received either T-Glu or R-Glu by prefilled pens as their bolus insulin for 26 weeks. The primary outcome was the proportion of patients with an immune response at Week 26. Secondary endpoints included changes in glycaemia control parameters, insulin dose stability, treatment satisfaction, and other immunogenicity and safety outcomes.
RESULTS: By Week 26, the immune response persisted in 16% of patients in the T-Glu group and 24% in the R-Glu group (p > 0.05), confirming similar immunogenicity. HbA1c reduction at Week 26 compared to baseline was similar between groups, with a mean change of 0.53% ± 1.19% in the T-Glu group and 0.38% ± 1.46% in the R-Glu group (mean difference: -0.15%, 95% CI: -0.50 to 0.20), demonstrating non-inferiority (according to a predefined margin of 0.4%). Fasting plasma glucose levels and the seven-point glucose profile showed no significant differences between groups (p > 0.05). Insulin dose remained stable throughout the study, and treatment satisfaction scores improved comparably in both groups (p > 0.05). The total number of AEs was similar, and hypoglycaemia was more frequent in the R-Glu group (p < 0.001), with no new safety concerns identified.
CONCLUSIONS: T-Glu demonstrated similar immunogenicity, efficacy, and safety to R-Glu in adults with T1DM, supporting its use as a biosimilar insulin glulisine.
CLINICALTRIALS: gov: NCT07070752.
MATERIALS AND METHODS: In this phase III, randomised, open-label trial, adult patients with T1DM received either T-Glu or R-Glu by prefilled pens as their bolus insulin for 26 weeks. The primary outcome was the proportion of patients with an immune response at Week 26. Secondary endpoints included changes in glycaemia control parameters, insulin dose stability, treatment satisfaction, and other immunogenicity and safety outcomes.
RESULTS: By Week 26, the immune response persisted in 16% of patients in the T-Glu group and 24% in the R-Glu group (p > 0.05), confirming similar immunogenicity. HbA1c reduction at Week 26 compared to baseline was similar between groups, with a mean change of 0.53% ± 1.19% in the T-Glu group and 0.38% ± 1.46% in the R-Glu group (mean difference: -0.15%, 95% CI: -0.50 to 0.20), demonstrating non-inferiority (according to a predefined margin of 0.4%). Fasting plasma glucose levels and the seven-point glucose profile showed no significant differences between groups (p > 0.05). Insulin dose remained stable throughout the study, and treatment satisfaction scores improved comparably in both groups (p > 0.05). The total number of AEs was similar, and hypoglycaemia was more frequent in the R-Glu group (p < 0.001), with no new safety concerns identified.
CONCLUSIONS: T-Glu demonstrated similar immunogenicity, efficacy, and safety to R-Glu in adults with T1DM, supporting its use as a biosimilar insulin glulisine.
CLINICALTRIALS: gov: NCT07070752.